Detalhe da pesquisa
1.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
N Engl J Med
; 384(12): 1101-1112, 2021 03 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33761207
2.
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs.
Allergy
; 2024 Jan 08.
Artigo
Inglês
| MEDLINE | ID: mdl-38186219
3.
Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the "Flip-Flop" phenomenon).
Allergy
; 79(1): 164-173, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37864390
4.
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
N Engl J Med
; 382(8): 706-716, 2020 02 20.
Artigo
Inglês
| MEDLINE | ID: mdl-32074418
5.
Herpes Simplex Virus 1 Can Bypass Impaired Epidermal Barriers upon Ex Vivo Infection of Skin from Atopic Dermatitis Patients.
J Virol
; 96(17): e0086422, 2022 09 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35969080
6.
Dermatomyositis autoantigen CHD4 forms immune stimulatory complexes with endogenous DNA.
Exp Dermatol
; 32(7): 965-974, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36995066
7.
IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis.
Allergy
; 2023 Jan 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36647778
8.
Immunoglobulin E autoantibodies in atopic dermatitis associate with Type-2 comorbidities and the atopic march.
Allergy
; 78(12): 3178-3192, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37489049
9.
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.
Allergy
; 78(11): 2875-2891, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37455359
10.
Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood.
Allergy
; 78(8): 2181-2201, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36946297
11.
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Br J Dermatol
; 189(5): 531-539, 2023 10 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37463508
12.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Br J Dermatol
; 188(6): 740-748, 2023 05 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36994947
13.
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
J Am Acad Dermatol
; 88(4): 816-823, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36473633
14.
Vitamin D3-Induced Promotor Dissociation of PU.1 and YY1 Results in FcεRI Reduction on Dendritic Cells in Atopic Dermatitis.
J Immunol
; 206(3): 531-539, 2021 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33443066
15.
Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
Clin Exp Dermatol
; 48(8): 881-888, 2023 Jul 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37032446
16.
A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.
J Eur Acad Dermatol Venereol
; 37(10): 2041-2046, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37319107
17.
Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study.
J Eur Acad Dermatol Venereol
; 37(3): 549-557, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-36376738
18.
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
J Allergy Clin Immunol
; 149(3): 977-987.e14, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34403658
19.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 397(10290): 2169-2181, 2021 06 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34023009
20.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Br J Dermatol
; 187(3): 338-352, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35484697